Ortho Evra and Pulmonary Embolism Caused by Ortho Evra Blood Clot - Venous Thromboembolism (VTE)

ORTHO EVRA INFORMATION

Ortho Evra Blood Clot - FDA

Ortho Evra Heart Attack

Ortho Evra Pulmonary Embolism

Ortho Evra Stroke

Ortho Evra Lawsuit

Pritzker | Olsen, P.A., a nationally-recognized product liability law firm, isinvestigating cases involving Ortho Evra birth control patches manufactured by Ortho McNeil Pharmaceuticals, a division of Johnson and Johnson. For Johnson and Johnson lawsuit information, contact Pritzker | Olsen, P.A. toll free at 1-888-377-8900 or fill out the firm's free case consultation form.

Below is the FDA notification of an update to the the label on the Ortho Evra birth control patch because of the risk of pulmonary embolism, blockage of the pulmonary artery (or one of its branches) caused by blood clot, specifically venous thromboembolism (VTE).

FDA Approves Update to Label on Ortho Evra Birth Control Patch Due to Risk of Pulmonary Embolism

The U.S. Food and Drug Administration (FDA) today approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism.

The label changes are based on a study conducted by the Boston Collaborative Drug Surveillance Program (BCDSP) on behalf of Johnson and Johnson. The patch was studied in women aged 15-44. These recent findings support an earlier study that also said women in this group were at higher risk for VTE [Ortho Evra blood clot].

"For women that choose to use contraceptives, it is important that they thoroughly discuss with their health care providers the risks and benefits involved," said Janet Woodcock, M.D., the FDA's deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the Center for Drug Evaluation and Research.

"This is an example of FDA working in tandem with the drug manufacturer to keep the public informed of new safety data and epidemiological studies that may impact health decisions about the use of FDA approved products."

In September 2006, FDA revised the label for Ortho Evra to warn women of the risk of VTE [Ortho Evra blood clot] based on two epidemiology studies. One study, conducted by i3 Ingenix, showed that some women using the patch were at a two-fold greater risk of developing VTE. The other study, conducted by BCDSP, showed they were not at increased risk compared to women using birth control pills containing 30-35 micrograms of estrogen and the progestin norgestimate.

Ortho Evra is a prescription patch that releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone) through the skin into the blood stream. Because the hormones are processed by the body differently than hormones from birth control pills, women using the product will be exposed to about 60 percent more estrogen than if they were using typical birth control pills containing 35 micrograms of estrogen. Increased levels of estrogen may increase the risk of side effects, including VTE [Ortho Evra blood clot]. Women should discuss with their health care provider the possible increased risk of VTE with Ortho Evra, which is applied once a week, and balance this risk against the increased chance of pregnancy if women do not take their birth control pill daily.

The FDA believes that Ortho Evra is a safe and effective method of contraception when used according to the labeling, which recommends that women with concerns or risk factors for serious blood clots talk with their health care provider about using Ortho Evra versus other contraceptive options.

The Ortho Evra Contraceptive Transdermal Patch is manufactured by Ortho McNeil Pharmaceuticals, a division of Johnson and Johnson.

Pritzker | Olsen, P.A. is a national law firm and represents people injured by defective medical products and the families of people whose deaths were caused by defective medical products. We have been contacted by several women and families regarding the Ortho Evra birth control patch, Ortho Evra blood clots and a Johnson and Johnson lawsuit..

We have gained a national reputation, and attorneys at our firm have been interviewed by The New York Times, The Wall Street Journal, Lawyers USA and other publications. In recognition of their accomplishments, attorneys at our firm have been named “Super Lawyers” by Law & Politics magazine and been listed in The Best Lawyers in America. They are sought-after speakers and regularly conduct seminars for other lawyers on complex legal issues. Contact us about Ortho Evra blood clots, Ortho Evra and pulmanary embolism and a Johnson and Johnson lawsuit.

Free Case Consultation

We are Not Paid Unless You Win

Our attorneys work on a continguency fee basis, meaning you do not have to pay our law firm for representing you unless we win you money.

Firm News

AV Preeminent Rating by Martindale-Hubbell

Attorneys Fred Pritzker and Eric Hageman have been given the highest rating by Martindale-Hubbell for attorney, AV Preeminent. An AV® certification mark is a significant rating accomplishment - a testament to the fact that a lawyer's peers rank him or her at the highest level of professional excellence.

Adjunct Teaching Position At U of M Law School

Attorney Brendan Flaherty has accepted an adjunct teaching position at the University of Minnesota Law School. For the 2011 spring semester, Flaherty will teach a course entitled "Practice and Professionalism," which will introduce students to foundational lawyering skills and professional responsibility issues.

Attorney Elliot Olsen Speaks at Conference

Attorney Elliot Olsen recently spoke at the Seventh Annual LifeScience Alley Conference in Minneapolis on Preemption and the Future of Medical Device Litigation. He appeared with Randall Pattee of Lindquist and Vennum and Jean Lance, VP of corporate legal and general counsel for Boston Scientific.

Named Super Lawyer

In recognition of their achievements, Attorneys Fred Pritzker, Elliot Olsen and Eric Hageman were named "Super Lawyers" by Law & Politics magazine. According to Super Lawyers, "The objective is to create a credible, comprehensive and diverse listing of outstanding attorneys that can be used as a resource to assist attorneys and consumers in the search for legal counsel."

Brendan Flaherty Named a Rising Star

In recognition of his achievements, Attorney Brendan Flaherty was named a 2010 Rising Star by Minnesota Law & Politics. Only 2.5 percent of the state’s lawyers are included on the list, which highlights Minnesota’s best up-and-coming legal talent.

Fred Pritzker Listed in The Best Lawyers in America

Fred Pritzker has been notified that he will again be listed in The Best Lawyers in America for his work in personal injury litigation.

This is attorney advertising. Past results do not guarantee a similar outcome. The result of each case is determined by the specific facts and the applicable law.